论文部分内容阅读
目的探讨大剂量甲基强的松龙冲击疗法治疗多发性硬化的临床疗效。方法选取2008年3月-2010年6月医院收治的多发性硬化者76例,随机分为大剂量甲基强的松龙冲击疗法组(试验组)和地塞米松治疗组(对照组)各38例。给予2组患者相应药物治疗,比较2组治疗效果、EDSS评分、平均治疗时间和生活质量评分以及复发情况。结果试验组总有效率为78.95%明显高于对照组的57.89%,差异有统计学意义(P<0.05)。治疗结束时试验组EDSS评分较对照组低、平均治疗时间较对照组缩短,差异有统计学意义(P<0.05)。试验组复发率明显低于对照组,差异有统计学意义(P<0.05)。结论大剂量甲基强的松龙冲击疗法治疗多发性硬化效果显著且安全可靠,值得临床推广、研究。
Objective To investigate the clinical efficacy of high-dose methylprednisolone impact therapy in the treatment of multiple sclerosis. Methods 76 patients with multiple sclerosis admitted to our hospital from March 2008 to June 2010 were randomly divided into high dose methylprednisolone impact therapy group (experimental group) and dexamethasone treatment group (control group) 38 cases. The two groups of patients were given the corresponding drug treatment, the treatment effect of two groups, EDSS score, average treatment time and quality of life scores and recurrence. Results The total effective rate of the experimental group was 78.95%, which was significantly higher than that of the control group (57.89%), the difference was statistically significant (P <0.05). At the end of treatment, the EDSS score of the experimental group was lower than that of the control group, and the average treatment time was shorter than that of the control group (P <0.05). The recurrence rate of the experimental group was significantly lower than that of the control group, the difference was statistically significant (P <0.05). Conclusion High-dose methylprednisolone impact therapy is effective and safe for multiple sclerosis. It is worthy of clinical promotion and research.